On Wednesday, Following Stocks were among the “Top 50 Losers” of U.S. Stock Market: Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN), Leju Holdings Limited (NYSE:LEJU), National Bank of Greece (ADR) (NYSE:NBG), Celladon Corp (NASDAQ:CLDN)

Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN), with shares declined -7.18%, closed at $1.94.

Leju Holdings Limited (NYSE:LEJU), with shares dropped -7.14%, settled at $6.76, hitting new 52-week low of $6.66.

National Bank of Greece (ADR) (NYSE:NBG), with shares dipped -6.92%, and closed at $1.21.

Celladon Corp (NASDAQ:CLDN), plummeted -6.85%, and closed at $23.26.

Latest NEWS regarding these Stocks are depicted underneath:

Aoxing Pharmaceutical Company, Inc. (NYSEMKT:AXN)

On last Friday, Aoxing Pharmaceutical Company, Inc. (AXN), declared that it has reached contracts to sell 1,029,412 shares of its ordinary stock. The sales are being made for the primary purpose of increasing the shareholders equity of the Corporation, and bringing it into compliance with the continued listing requirements of NYSE MKT. The sales will be accomplished after the NYSE MKT approves the listing of the additional shares.

508,000 shares will be sold to officers and employees of Aoxing Pharma at a price of $1.36 per share, which was the market price when the sales contracts were made on March 11, 2015. Comprised of among the purchasers will be Wilfred Chow, CFO (100,000 shares) and Guoan Zhang, VP-Finance (20,000 shares). The proceeds for Aoxing Pharma total $690,880, which will be utilized for working capital purposes. The additional 521,412 shares will be issued to a creditor in satisfaction of $709,120 debt.

Aoxing Pharmaceutical Corporation, Inc. is a US incorporated specialty pharmaceutical corporation with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-administration products.

Leju Holdings Limited (NYSE:LEJU)

On Wednesday, Leju Holdings Limited (NYSE:LEJU), a leading online-to-offline (“O2O”) real estate services provider in China, declared its unaudited financial results for the fiscal quarter and full year ended December 31, 2014.

Fourth Quarter 2014 Financial Highlights:

• Total proceeds raised by 36% year-on-year to $171.8 million,
• Proceeds from e-commerce services raised by 61% year-on-year to $124.5 million,
• Proceeds from online advertising services raised by 1% year-on-year to $43.8 million,
• Non-GAAP[1] revenue from operations raised by 8% year-on-year to $36.8 million,
• Non-GAAP net revenue attributable to Leju shareholders raised by 12% year-on-year to $31.3 million, or $0.23 per diluted American depositary share (“ADS”).

Full Year 2014 Financial Highlights:

• Total proceeds raised by 48% year-on-year to $496.0 million,
• Proceeds from e-commerce services raised by 92% year-on-year to $326.7 million,
• Proceeds from online advertising services raised by 7% year-on-year to $155.1 million,
• Non-GAAP revenue from operations raised by 44% year-on-year to $107.0 million,
• Non-GAAP net revenue attributable to Leju shareholders raised by 44% year-on-year to $90.7 million, or $0.68 per diluted ADS.

Leju Holdings Limited, (LEJU), is a leading online-to-offline, or O2O, real estate services provider in China, offering real estate e-commerce, online advertising and online listing services. Leju’s integrated online platform comprises various mobile applications together with local websites covering more than 250 cities, improved by complementary offline services to facilitate residential property transactions.

National Bank of Greece S.A. (NYSE:NBG)

National Bank of Greece S.A. (NBG), dipped in the course of Wednesday trading following the news that Greece and its creditors hit a rough patch in their crucial technical talks. According to the Wall Street Journal, Official said Wednesday that the talks are going poorly and each side is holding responsible the other for the problems.

The European Commission, the European Central Bank, and the International Monetary Fund, all of which are in Athens, are getting hardly any information on the Greek government’s finances and other important subjects, two European officials said.

National Bank of Greece S.A., together with its auxiliaries, offers diversified financial services primarily in Greece. The corporation is involved in retail and commercial banking, investment administration, investment banking, insurance, investment activities, and securities trading activities. It offers demand deposits, savings deposits, and time deposits, and current accounts; investment products; consumer loans, personal loans, mortgage loans, automobile loans, overdraft facilities, and foreign currency loans, in addition to letters of credit and guarantees; credit cards; currency swaps and options; and ATMs.

Celladon Corporation (NASDAQ:CLDN)

Celladon Corporation (CLDN), declared that on March 9, 2015 the Compensation Committee of the Corporation’s Board of Directors approved the grant of inducement stock options to purchase a total of 40,000 shares of ordinary stock to three new employees, with two of such grants having a grant date of March 9, 2015 and the third having a grant date of March 11, 2015, with each such grant date corresponding to the employees’ respective hire dates.

Each of the March 9 Grants has an exercise price per share equal to $24.89, the fair market value on the grant date of the March 9 Grants. The March 11 Grant has an exercise price per share equal to $25.99, the fair market value on the grant date of the March 11 Grant. Each stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the employee’s first day of employment with the Corporation and 1/48 of the shares vesting monthly thereafter, subject to the new employee’s continued service relationship with the Corporation on each such date. Each stock option has a ten year term and is subject to the terms and conditions of the Corporation’s 2013 Equity Incentive Plan and applicable stock option contract.

Celladon Corporation, a clinical-stage biotechnology corporation, focuses on developing treatments for heart failure, diabetes, and neurodegenerative diseases.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.